In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin

Tae Hoon Kim, Young Pil Yun, Kyu Sik Shim, Hak Jun Kim, Sung Eun Kim, Kyeongsoon Park, Hae Ryong Song

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to prepare inclusion nanocomplexes of hyaluronic acid-β-cyclodextrin and simvastatin (HA-β-CD/SIM) and evaluate in vitro anti-inflammation effects on lipopolysaccharide (LPS)-activated synoviocytes and chondrogenic differentiation effects on rat adipose-derived stem cells (rADSCs). The β-CD moieties in HA-β-CD could incorporate SIM to form HA-β-CD/SIM nanocomplexes with diameters of 297–350 nm. HA-β-CD/SIM resulted in long-term release of SIM from the nanocomplexes for up to 63 days in a sustained manner. In vitro studies revealed that HA-β-CD/SIM nanocomplexes were able to effectively and dose-dependently suppress the mRNA expression levels of pro-inflammatory markers such as matrix metallopeptidase-3 (MMP-3), MMP-13, cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) in LPS-stimulated synoviocytes. HA-β-CD/SIM-treated rADSCs significantly and dose-dependently enhanced mRNA expressions of aggrecan, collagen type II (COL2A1), and collagen type X (COL10A1), implying that HA-β-CD/SIM greatly induced the chondrogenic differentiation of rADSCs. Conclusively, HA-β-CD/SIM nanocomplexes will be a promising therapeutic material to alleviate inflammation as well as promote chondrogenesis.

Original languageEnglish
Pages (from-to)263-274
Number of pages12
JournalTissue Engineering and Regenerative Medicine
Volume15
Issue number3
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Hyaluronic acid
Simvastatin
Cyclodextrins
Hyaluronic Acid
Inflammation
Stem cells
Rats
Stem Cells
Metalloproteases
Collagen
Lipopolysaccharides
Cartilage Oligomeric Matrix Protein
Collagen Type X
Disintegrins
Aggrecans
Chondrogenesis
Messenger RNA
Collagen Type II
Cyclooxygenase 2
In Vitro Techniques

Keywords

  • Adipose-derived stem cells
  • Chondrogenesis
  • Hyaluronic acid-β-cyclodextrin
  • Simvastatin

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin. / Kim, Tae Hoon; Yun, Young Pil; Shim, Kyu Sik; Kim, Hak Jun; Kim, Sung Eun; Park, Kyeongsoon; Song, Hae Ryong.

In: Tissue Engineering and Regenerative Medicine, Vol. 15, No. 3, 01.06.2018, p. 263-274.

Research output: Contribution to journalArticle

@article{8e5021a9c0c2406d95ede7cb26d6fb83,
title = "In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin",
abstract = "The aim of this study was to prepare inclusion nanocomplexes of hyaluronic acid-β-cyclodextrin and simvastatin (HA-β-CD/SIM) and evaluate in vitro anti-inflammation effects on lipopolysaccharide (LPS)-activated synoviocytes and chondrogenic differentiation effects on rat adipose-derived stem cells (rADSCs). The β-CD moieties in HA-β-CD could incorporate SIM to form HA-β-CD/SIM nanocomplexes with diameters of 297–350 nm. HA-β-CD/SIM resulted in long-term release of SIM from the nanocomplexes for up to 63 days in a sustained manner. In vitro studies revealed that HA-β-CD/SIM nanocomplexes were able to effectively and dose-dependently suppress the mRNA expression levels of pro-inflammatory markers such as matrix metallopeptidase-3 (MMP-3), MMP-13, cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) in LPS-stimulated synoviocytes. HA-β-CD/SIM-treated rADSCs significantly and dose-dependently enhanced mRNA expressions of aggrecan, collagen type II (COL2A1), and collagen type X (COL10A1), implying that HA-β-CD/SIM greatly induced the chondrogenic differentiation of rADSCs. Conclusively, HA-β-CD/SIM nanocomplexes will be a promising therapeutic material to alleviate inflammation as well as promote chondrogenesis.",
keywords = "Adipose-derived stem cells, Chondrogenesis, Hyaluronic acid-β-cyclodextrin, Simvastatin",
author = "Kim, {Tae Hoon} and Yun, {Young Pil} and Shim, {Kyu Sik} and Kim, {Hak Jun} and Kim, {Sung Eun} and Kyeongsoon Park and Song, {Hae Ryong}",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s13770-018-0119-9",
language = "English",
volume = "15",
pages = "263--274",
journal = "Tissue Engineering and Regenerative Medicine",
issn = "1738-2696",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin

AU - Kim, Tae Hoon

AU - Yun, Young Pil

AU - Shim, Kyu Sik

AU - Kim, Hak Jun

AU - Kim, Sung Eun

AU - Park, Kyeongsoon

AU - Song, Hae Ryong

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The aim of this study was to prepare inclusion nanocomplexes of hyaluronic acid-β-cyclodextrin and simvastatin (HA-β-CD/SIM) and evaluate in vitro anti-inflammation effects on lipopolysaccharide (LPS)-activated synoviocytes and chondrogenic differentiation effects on rat adipose-derived stem cells (rADSCs). The β-CD moieties in HA-β-CD could incorporate SIM to form HA-β-CD/SIM nanocomplexes with diameters of 297–350 nm. HA-β-CD/SIM resulted in long-term release of SIM from the nanocomplexes for up to 63 days in a sustained manner. In vitro studies revealed that HA-β-CD/SIM nanocomplexes were able to effectively and dose-dependently suppress the mRNA expression levels of pro-inflammatory markers such as matrix metallopeptidase-3 (MMP-3), MMP-13, cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) in LPS-stimulated synoviocytes. HA-β-CD/SIM-treated rADSCs significantly and dose-dependently enhanced mRNA expressions of aggrecan, collagen type II (COL2A1), and collagen type X (COL10A1), implying that HA-β-CD/SIM greatly induced the chondrogenic differentiation of rADSCs. Conclusively, HA-β-CD/SIM nanocomplexes will be a promising therapeutic material to alleviate inflammation as well as promote chondrogenesis.

AB - The aim of this study was to prepare inclusion nanocomplexes of hyaluronic acid-β-cyclodextrin and simvastatin (HA-β-CD/SIM) and evaluate in vitro anti-inflammation effects on lipopolysaccharide (LPS)-activated synoviocytes and chondrogenic differentiation effects on rat adipose-derived stem cells (rADSCs). The β-CD moieties in HA-β-CD could incorporate SIM to form HA-β-CD/SIM nanocomplexes with diameters of 297–350 nm. HA-β-CD/SIM resulted in long-term release of SIM from the nanocomplexes for up to 63 days in a sustained manner. In vitro studies revealed that HA-β-CD/SIM nanocomplexes were able to effectively and dose-dependently suppress the mRNA expression levels of pro-inflammatory markers such as matrix metallopeptidase-3 (MMP-3), MMP-13, cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) in LPS-stimulated synoviocytes. HA-β-CD/SIM-treated rADSCs significantly and dose-dependently enhanced mRNA expressions of aggrecan, collagen type II (COL2A1), and collagen type X (COL10A1), implying that HA-β-CD/SIM greatly induced the chondrogenic differentiation of rADSCs. Conclusively, HA-β-CD/SIM nanocomplexes will be a promising therapeutic material to alleviate inflammation as well as promote chondrogenesis.

KW - Adipose-derived stem cells

KW - Chondrogenesis

KW - Hyaluronic acid-β-cyclodextrin

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=85047522191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047522191&partnerID=8YFLogxK

U2 - 10.1007/s13770-018-0119-9

DO - 10.1007/s13770-018-0119-9

M3 - Article

AN - SCOPUS:85047522191

VL - 15

SP - 263

EP - 274

JO - Tissue Engineering and Regenerative Medicine

JF - Tissue Engineering and Regenerative Medicine

SN - 1738-2696

IS - 3

ER -